• Antengene dosed the first patient in China in the pivotal Phase III CLINCH-3 trial of ATG-022 for CLDN18.2-positive advanced gastric cancers.
• Earlier Phase I/II results have already been presented, supporting progression into late-stage testing on efficacy and tolerability grounds.
• The Phase III study will compare ATG-022 with investigator’s choice therapy, aiming to confirm clinical benefit without combination treatment.
• ATG-022 previously received Breakthrough Therapy Designation in China, supporting a faster regulatory path toward a future marketing application.
• The program is planned to expand beyond China into a multi-regional trial, broadening the potential commercial footprint if results hold.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Antengene Corporation Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609202030PR_NEWS_USPR_____CN52156) on September 21, 2026, and is solely responsible for the information contained therein.